Text Size

Acute Effect of Fructose on Lipid Metabolism and Gender Differences

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Luc Tappy, MD, University of Lausanne
ClinicalTrials.gov Identifier:
NCT00620360
First received: February 8, 2008
Last updated: February 23, 2012
Last verified: February 2012
History of Changes
  Purpose

It has been widely documented that fructose overfeeding increases plasma triglycerides and hepatic de novo lipogenesis, and impairs insulin sensitivity in healthy male volunteers. The effect of gender on the metabolic responses to fructose remains an important open question, however.

The objective of this study is to compare the effect of an acute oral fructose load on carbohydrate and lipid metabolism in healthy young males and females.


Condition Intervention
Lipid Metabolism
 Dietary Supplement: fructose
Dietary Supplement: Fructose

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: Acute Effect of Fructose on Lipid Metabolism and Gender Differences

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by University of Lausanne:

Primary Outcome Measures:
  • Hepatic de novo lipogenesis [ Time Frame: acute effect of dietary fructose (within 6 hours) ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Whole body lipid oxidation, glucose turnover, glycerol turnover, plasma substrates, hormone and energy expenditure (free fatty acid, glucose, lactate, beta-hydroxybutyrate, glycerol, VLDL- Triglycerides and insulin) expression of key adipose genes [ Time Frame: acute effect of fructose (within 6 hours) ] [ Designated as safety issue: No ]

Enrollment: 18
Study Start Date: January 2008
Study Completion Date: December 2008
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: fructose
acute fructose administration
 Dietary Supplement: fructose
acute administration of 4 times 0.3g fructose/kg lean body mass
Dietary Supplement: Fructose
acute administration of 4 times 0.3 g/kg fat-free mass oral fructose

Detailed Description:

The study is aimed at comparing the effects of oral fructose on several specific metabolic pathways in males and females.Participants will receive an isoenergetic diet containing 55% carbohydrate, 15% protein and 35% lipids for three days prior to testing. After this period of controlled diet, they will be studied for 2 hours in the post-absorptive state (Time 0-120 min) and over a 6 hours period (Time 120-480 min) during which they will receive 4 loads of 0,30 g/kg fat free mass U-13C labelled fructose, at times 120, 180, 240, 300. Throughout the study, deuterated glucose and glycerol will be infused to monitor whole body glucose production and glycerol turnover.

The following parameters will be monitored in basal conditions and after the ingestion of the load of fructose:

  • Glycerol turnover(glycerol 2H5)
  • de novo lipogenesis (incorporation of 13C into palmitate of VLDLs)
  • whole body energy expenditure and net substrate oxydation (indirect calorimetry)
  • net fructose oxidation (breath 13CO2)
  • glucose turnover: (6,6 2H2 Glucose)
  • plasma glucose, free fatty acids, ketone bodies, lactate, insulin, triacylglycerol, total cholesterol, VLDL, LDL, and HDL subfractions

An adipose tissue (periumbilical subcutaneous) biopsy will be obtaine by needle aspiration under local anesthesia in fasting conditions (time 0 min) and after fructose (time 480 min) to assess the effects of fructose on adipose gene expression profile. Key genes involved in the regulation of carbohydrate (GLUT 4, hexokinase, PDH-kinase), lipid (FAT-CD36, FABP, acetylCoA carboxylase, malonyl-CoA decarboxylase, PPARg) and energy metabolism (PGC-1a, UCP2)will be monitored

Results obtained in males and females will be compared with two-way analysis of variance

  Eligibility

Ages Eligible for Study:   18 Years to 35 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Males and females
  • Age 18-35
  • Healthy
  • Body mass indexes (BMI) between 19 and 25 kg/m2
  • Informed consent obtained

Exclusion Criteria:

  • Smokers
  • Alcohol intake > 30g/day
  • Drug abuse
  • Diabetes mellitus
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00620360

Locations
Switzerland
Centre Hospitalier Universitaire Vaudois
Lausanne, Vaud, Switzerland, 1005
Sponsors and Collaborators
University of Lausanne
Investigators
Principal Investigator: Luc Tappy, MD University of Lausanne
  More Information

No publications provided

Responsible Party: Luc Tappy, MD, Professor of physiology, University of Lausanne
ClinicalTrials.gov Identifier: NCT00620360     History of Changes
Other Study ID Numbers: 279/07/CE/FBM
Study First Received: February 8, 2008
Last Updated: February 23, 2012
Health Authority: Switzerland: Ethikkommission

Keywords provided by University of Lausanne:
dietary fructose
plasma lipids
healthy humans
gender differences
hepatic de novo lipogenesis

ClinicalTrials.gov processed this record on May 23, 2013